Biomarin Total Operating Expenses from 2010 to 2026
| BMRN Stock | USD 57.61 1.07 1.89% |
Total Operating Expenses | First Reported 1999-03-31 | Previous Quarter 398.4 M | Current Value 682.7 M | Quarterly Volatility 171.4 M |
Check Biomarin Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biomarin Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 116.4 M, Interest Expense of 17.9 M or Selling General Administrative of 642.8 M, as well as many indicators such as Price To Sales Ratio of 4.78, Dividend Yield of 0.0 or PTB Ratio of 3.91. Biomarin financial statements analysis is a perfect complement when working with Biomarin Pharmaceutical Valuation or Volatility modules.
Biomarin | Total Operating Expenses | Build AI portfolio with Biomarin Stock |
Evaluating Biomarin Pharmaceutical's Total Operating Expenses across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Biomarin Pharmaceutical's fundamental strength.
Latest Biomarin Pharmaceutical's Total Operating Expenses Growth Pattern
Below is the plot of the Total Operating Expenses of Biomarin Pharmaceutical over the last few years. It is the total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses. Biomarin Pharmaceutical's Total Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biomarin Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.
| Total Operating Expenses | 10 Years Trend |
|
Total Operating Expenses |
| Timeline |
Biomarin Total Operating Expenses Regression Statistics
| Arithmetic Mean | 1,213,576,300 | |
| Geometric Mean | 895,791,110 | |
| Coefficient Of Variation | 50.33 | |
| Mean Deviation | 505,734,482 | |
| Median | 1,379,623,000 | |
| Standard Deviation | 610,760,717 | |
| Sample Variance | 373028.7T | |
| Range | 2.1B | |
| R-Value | 0.94 | |
| Mean Square Error | 48278.5T | |
| R-Squared | 0.88 | |
| Slope | 113,373,853 | |
| Total Sum of Squares | 5968458.5T |
Biomarin Total Operating Expenses History
About Biomarin Pharmaceutical Financial Statements
Biomarin Pharmaceutical investors utilize fundamental indicators, such as Total Operating Expenses, to predict how Biomarin Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Operating Expenses | 2.1 B | 2.2 B |
Pair Trading with Biomarin Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biomarin Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving together with Biomarin Stock
Moving against Biomarin Stock
| 0.69 | CUE | Cue Biopharma | PairCorr |
| 0.66 | EDIT | Editas Medicine | PairCorr |
| 0.62 | ENSC | Ensysce Biosciences | PairCorr |
| 0.62 | HURA | TuHURA Biosciences | PairCorr |
| 0.54 | XGN | Exagen Inc | PairCorr |
The ability to find closely correlated positions to Biomarin Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biomarin Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biomarin Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biomarin Pharmaceutical to buy it.
The correlation of Biomarin Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biomarin Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biomarin Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biomarin Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Biomarin Pharmaceutical Correlation against competitors. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Will Biotechnology sector continue expanding? Could Biomarin diversify its offerings? Factors like these will boost the valuation of Biomarin Pharmaceutical. Projected growth potential of Biomarin fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Biomarin Pharmaceutical data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.243 | Earnings Share 2.69 | Revenue Per Share | Quarterly Revenue Growth 0.041 | Return On Assets |
Understanding Biomarin Pharmaceutical requires distinguishing between market price and book value, where the latter reflects Biomarin's accounting equity. The concept of intrinsic value—what Biomarin Pharmaceutical's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Biomarin Pharmaceutical's price substantially above or below its fundamental value.
It's important to distinguish between Biomarin Pharmaceutical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biomarin Pharmaceutical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biomarin Pharmaceutical's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.